Regulation of serum paraoxonase activity by genetic, nutritional, and lifestyle factors in the general population.

BACKGROUND Paraoxonase may protect lipoproteins and cell membranes from peroxidation, and alterations in the activity of this enzyme have been associated with some chronic diseases. Serum paraoxonase appears to be mainly under genetic control, but some studies suggest that environmental factors may also modulate its activity. The aim of the present study was to investigate whether diet and lifestyle affect serum paraoxonase activity. METHODS We studied a population-based sample of 388 individuals (194 women and 194 men; age range, 18-75 years) and assessed their daily dietary intake using a 3-day estimated food record. The variables studied included serum paraoxonase activity, paraoxonase polymorphisms at positions 55 and 192, age, gender, smoking status, physical exercise, body mass index, energy consumption, nutrient intake (total lipids, saturated fatty acids, beta-carotenes, vitamins C and E), and serum lipid concentrations. RESULTS Multiple linear regression analysis showed that only genetic polymorphisms, serum cholesterol, HDL-cholesterol concentrations, and cigarette smoking were significant predictors of serum paraoxonase activity. HDL-cholesterol concentrations were also related to body mass index, daily energy consumption, and saturated fatty acid intake. CONCLUSIONS The between-individual variability of serum paraoxonase activity is regulated mainly by genetic determinants. Although HDL-cholesterol and tobacco smoking may contribute to the modulation of this enzyme, the other nutritional and lifestyle factors do not seem to play a significant role.

[1]  G. Jarvik,et al.  Functional genomic of the paraoxonase (PON1) polymorphisms: effects on pesticide sensitivity, cardiovascular disease, and drug metabolism. , 2003, Annual review of medicine.

[2]  P. McElduff,et al.  Low Paraoxonase Activity Predicts Coronary Events in the Caerphilly Prospective Study , 2003, Circulation.

[3]  G. Siest,et al.  PON1-192 Phenotype and Genotype Assessments in 918 Subjects of the Stanislas Cohort Study , 2003, Clinical chemistry and laboratory medicine.

[4]  C. Carlson,et al.  Functional genomics of the paraoxonase polymorphisms , 2003 .

[5]  J. Mathers.  Pulses and carcinogenesis: potential for the prevention of colon, breast and other cancers , 2002, British Journal of Nutrition.

[6]  R. Elosua,et al.  Tobacco and alcohol consumption: impact on other cardiovascular and cancer risk factors in a southern European Mediterranean population , 2002, British Journal of Nutrition.

[7]  G. Schellenberg,et al.  Vitamin C and E Intake Is Associated With Increased Paraoxonase Activity , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[8]  P. Durrington,et al.  The hunt for nutritional and pharmacological modulators of paraoxonase. , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[9]  J. Ruidavets,et al.  Alcohol consumption is associated with enrichment of high-density lipoprotein particles in polyunsaturated lipids and increased cholesterol esterification rate. , 2002, Alcoholism, clinical and experimental research.

[10]  A. Evans,et al.  High expressor paraoxonase PON1 gene promoter polymorphisms are associated with reduced risk of vascular disease in younger coronary patients. , 2002, Atherosclerosis.

[11]  M. Jauhiainen,et al.  Dietary determinants of serum paraoxonase activity in healthy humans. , 2002, Atherosclerosis.

[12]  J. Joven,et al.  Serum paraoxonase activity: a new additional test for the improved evaluation of chronic liver damage. , 2002, Clinical chemistry.

[13]  G. Jarvik,et al.  Effects of 5' regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. , 2001, American journal of human genetics.

[14]  Sheila M. Williams,et al.  Hormone-replacement therapy increases serum paraoxonase arylesterase activity in diabetic postmenopausal women , 2001 .

[15]  G. Jarvik,et al.  Polymorphisms in the human paraoxonase (PON1) promoter. , 2001, Pharmacogenetics.

[16]  J. Marrugat,et al.  Effect of Simvastatin Therapy on Paraoxonase Activity and Related Lipoproteins in Familial Hypercholesterolemic Patients , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[17]  P. Froguel,et al.  Promoter polymorphism T(-107)C of the paraoxonase PON1 gene is a risk factor for coronary heart disease in type 2 diabetic patients. , 2000, Diabetes.

[18]  A. Righetti,et al.  Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease. , 2000, Circulation.

[19]  R. Coleman,et al.  Pomegranate juice consumption reduces oxidative stress, atherogenic modifications to LDL, and platelet aggregation: studies in humans and in atherosclerotic apolipoprotein E-deficient mice. , 2000, The American journal of clinical nutrition.

[20]  I. Leviev,et al.  Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[21]  M. Laule,et al.  Mutations in the human paraoxonase 1 gene: frequencies, allelic linkages, and association with coronary artery disease. , 1999, Pharmacogenetics.

[22]  H. Hendriks,et al.  Daily moderate alcohol consumption increases serum paraoxonase activity; a diet-controlled, randomised intervention study in middle-aged men. , 1999, Atherosclerosis.

[23]  P. Durrington,et al.  Polymorphisms of paraoxonase genes and low-density lipoprotein lipid peroxidation , 1999, The Lancet.

[24]  D. Shih,et al.  Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis , 1998, Nature.

[25]  J. Joven,et al.  Evaluation of a homogeneous assay for high-density lipoprotein cholesterol: limitations in patients with cardiovascular, renal, and hepatic disorders. , 1998, Clinical chemistry.

[26]  J. Bollinger,et al.  Inhibition of arylesterase by aliphatic alcohols. , 1998, Chemico-biological interactions.

[27]  P. Durrington,et al.  Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification , 1998, FEBS letters.

[28]  R. James,et al.  Two alleles of the human paraoxonase gene produce different amounts of mRNA. An explanation for differences in serum concentrations of paraoxonase associated with the (Leu-Met54) polymorphism. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[29]  P. Durrington,et al.  Presence of paraoxonase in human interstitial fluid , 1997, FEBS letters.

[30]  Yasuhiro Watanabe,et al.  Cigarette smoke extract inhibits plasma paraoxonase activity by modification of the enzyme's free thiols. , 1997, Biochemical and biophysical research communications.

[31]  P. Kris-Etherton,et al.  Individual fatty acid effects on plasma lipids and lipoproteins: human studies. , 1997, The American journal of clinical nutrition.

[32]  J. Hokanson,et al.  Paraoxonase genotypes, lipoprotein lipase activity, and HDL. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[33]  M. Jauhiainen,et al.  The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns. , 1996, The Journal of clinical investigation.

[34]  D. Shih,et al.  Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model. , 1996, The Journal of clinical investigation.

[35]  A. Marian,et al.  A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. , 1995, The Journal of clinical investigation.

[36]  J. Berliner,et al.  Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. , 1995, The Journal of clinical investigation.

[37]  O. Lockridge,et al.  Reconsideration of the catalytic center and mechanism of mammalian paraoxonase/arylesterase. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[38]  J. Derr,et al.  Plasma cholesterol-predictive equations demonstrate that stearic acid is neutral and monounsaturated fatty acids are hypocholesterolemic. , 1995, The American journal of clinical nutrition.

[39]  A. Lavy,et al.  Consumption of red wine with meals reduces the susceptibility of human plasma and low-density lipoprotein to lipid peroxidation. , 1995, The American journal of clinical nutrition.

[40]  F. Thompson,et al.  Dietary assessment resource manual. , 1994, The Journal of nutrition.

[41]  C. Abbott,et al.  Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. , 1993, Atherosclerosis.

[42]  M. Blatter,et al.  Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. , 1993, European journal of biochemistry.

[43]  P. Durrington,et al.  Paraoxonase prevents accumulation of lipoperoxides in low‐density lipoprotein , 1991, FEBS letters.

[44]  A. Brantsaeter,et al.  The serum LDL/HDL cholesterol ratio is influenced more favorably by exchanging saturated with unsaturated fat than by reducing saturated fat in the diet of women. , 2003, The Journal of nutrition.

[45]  P. Moulin,et al.  Paraoxonase protection of LDL against peroxidation is independent of its esterase activity towards paraoxon and is unaffected by the Q-->R genetic polymorphism. , 1999, Journal of lipid research.

[46]  P. Froguel,et al.  Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. , 1997, The Journal of clinical investigation.

[47]  M. Feinberg,et al.  Répertoire général des aliments : 5. Aliments de marque , 1997 .

[48]  P. Kris-Etherton,et al.  Individual fattyacideffectson plasmalipidsand lipoproteins: human ,2 , 1997 .

[49]  J. Ireland-Ripert,et al.  Répertoire général des aliments : table de composition = Composition tables , 1995 .

[50]  D. Adler,et al.  The molecular basis of the human serum paraoxonase activity polymorphism , 1993, Nature Genetics.